Serzone Liver Failure Relabeling Suggests Periodic Testing, Adds Black Box
Executive Summary
Additional warnings for Bristol-Myers Squibb's antidepressant Serzone (nefazodone) suggest, but do not require, liver monitoring
You may also be interested in...
FDA Import Crackdown Escalates With DoJ Suit Vs. Canadian Pharmacy Site
FDA is escalating its enforcement against drug reimportation through a Department of Justice suit against a Canadian pharmacy operation
FDA Import Crackdown Escalates With DoJ Suit Vs. Canadian Pharmacy Site
FDA is escalating its enforcement against drug reimportation through a Department of Justice suit against a Canadian pharmacy operation
Bristol Serzone discussions with Health Canada
Bristol has entered discussions with Canadian regulators over the risk/benefit profile and marketing status of its antidepressant Serzone, the company says. Serzone (nefazodone) has been associated with reports of hepatic failure; the company added a "black box" warning to labeling for the antidepressant in 2001 following 18 reports of liver failure, including 13 deaths (1"The Pink Sheet" Dec. 10, 2001, p. 22). Bristol withdrew Serzone from the market in Europe earlier this year (2"The Pink Sheet" Jan. 13, 2003, p. 23)...